Plus   Neg

Conatus Pharmaceuticals Inc. (CNAT) Vaulted To A New High On Novartis Deal

Conatus Pharmaceuticals Inc. (CNAT) announced after the bell Monday that it has entered into an exclusive option, collaboration and license agreement with Novartis to develop and commercialize emricasan.

Conatus Pharmaceuticals gapped open dramatically higher Tuesday, but traded in a range throughout the session. The stock closed up by 2.77 at $4.73 on the highest volume of the year. Conatus Pharmaceuticals leaped to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT